We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.05 | 0.71% | 150.0028 | 150.10 | 148.89 | 148.98 | 6,532,894 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of the blockbuster blood-cancer drug Imbruvica in certain patients with chronic lymphocytic leukemia.
Janssen, which jointly develops and markets Imbruvica with AbbVie Inc., said the recommendation covers the drug in an oral fixed-duration combination with venetoclax for adults with previously untreated chronic lymphocytic leukemia, a type of cancer that starts from white blood cells in the bone marrow.
Janssen said the combination, if approved, would be the first all-oral, once daily, fixed-duration combination regimen for first-line treatment of the disease. The European Commission, which generally follows the CHMP's advice, will make a final decision on approval.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 08:36 ET (12:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
